Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C.

PURPOSE The stability of an admixture containing reconstituted daptomycin and heparin in lactated Ringer's injection was evaluated. METHODS Two samples of the admixture of daptomycin 5 mg/mL and heparin sodium 100 USP units/mL diluted in lactated Ringer's injection were prepared and divided into 5-mL portions for storage in syringes at 4 and -20 °C for 14 days. The percentage of the initial concentration of the drugs remaining in the syringes was assessed using a high-performance liquid chromatographic (HPLC) method with diode-array detection previously validated as stability indicating for both drugs. Forced degradation studies were performed independently with each drug diluted in lactated Ringer's injection. One sample from each stored syringe was analyzed in triplicate on days 0, 1, 2, 3, 4, 7, and 14; quality-control samples of each concentration tested were used throughout the analysis. The admixture samples were visually inspected for color, clarity, and the formation of particulate matter. RESULTS The HPLC analysis indicated no significant reduction (loss of ≤5%) in the concentration of daptomycin and heparin diluted in lactated Ringer's injection stored in syringes refrigerated at 4 °C and frozen at -20 °C. None of the chromatographic peaks observed in samples subjected to forced degradation were detected in any sample during the 14-day study. All of the syringe-stored samples remained clear and colorless on visual inspection for the duration of the study. CONCLUSION The admixture of daptomycin 5 mg/mL and heparin sodium 100 USP units/mL was stable when stored in polypropylene syringes for up to 14 days at 4 and -20 °C.

[1]  A. Bettencourt,et al.  Daptomycin: a review of properties, clinical use, drug delivery and resistance. , 2012, Mini reviews in medicinal chemistry.

[2]  F. Stanley,et al.  The use of SAX-HPLC-CD as a heparin screening strategy. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  A. Skoutelis,et al.  Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. , 2011, Journal of pharmaceutical and biomedical analysis.

[4]  J. Rodríguez-Baño,et al.  A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. , 2010, Journal of microbiological methods.

[5]  A. Skoutelis,et al.  Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: Application to a pharmacokinetic study. , 2010, Journal of pharmaceutical and biomedical analysis.

[6]  P. Stewart,et al.  Daptomycin Rapidly Penetrates a Staphylococcus epidermidis Biofilm , 2009, Antimicrobial Agents and Chemotherapy.

[7]  S. Bode-Böger,et al.  Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  L. Mermel,et al.  In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  J. Lai,et al.  Physical and Chemical Compatibility of Daptomycin with Nine Medications , 2004, The Annals of pharmacotherapy.

[10]  A. Randolph,et al.  Guidelines for the prevention of intravascular catheter-related infections. , 2002, American journal of infection control.

[11]  R. D. McCormick,et al.  Guidelines for the prevention of intravascular catheter-related infections. , 2002, Infection control and hospital epidemiology.

[12]  J. Costerton,et al.  Antimicrobial Activity of a Novel Catheter Lock Solution , 2002, Antimicrobial Agents and Chemotherapy.

[13]  L. Mermel,et al.  Guidelines for the management of intravascular catheter-related infections. , 2001, Infection control and hospital epidemiology.

[14]  F. Burczynski,et al.  Antibiotic‐Heparin Lock: In Vitro Antibiotic Stability Combined with Heparin in a Central Venous Catheter , 2000, Pharmacotherapy.

[15]  A. Karchmer,et al.  Catheter-associated Staphylococcus aureus bacteremia. , 1996, Hospital practice.

[16]  J. Marschall,et al.  Infection and Drug Resistance Dovepress Current Strategies for the Prevention and Management of Central Line-associated Bloodstream Infections , 2022 .